Testing the Dexcom G7 glucose sensor in critically ill surgery and transplant patients
Tests how accurately the Dexcom G7 glucose sensor tracks blood sugar in intensive care patients.
Plain-language title generated from the registry record
Registry title: Evaluate the Performance of the Dexcom G7 Continuous Glucose Monitoring (CGM) System in Critically Ill Patients Undergoing Major Abdominal Surgery and Solid Organ Transplantation Which Require Blood Glucose Monitoring for Intensive Insulin Therapy.
Key facts
- Where
- Prague, CzechiaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in intensive care after major abdominal surgery or an organ transplant who need blood sugar checks for insulin treatment. It tests how accurate a continuous glucose sensor is.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- People admitted to the intensive care unit who need blood glucose monitoring for insulin therapy.
Main reasons for not taking part
- Taking high-dose ascorbic acid
- Taking acetaminophen above 4g/day
- A physical or mental health condition that stops continuous wear of the sensor, as judged by the physician
Read by machine on 9 November 2026.
Where in Czechia
- Institute of Clinical and Experimental MedicePrague, CzechiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institute for Clinical and Experimental Medicine
- Trial code
- NCT07611721
- Record updated
- 28 May 2026
- Original description
Main objective:Read full original descriptionShow less
Determining the Reliability and Accuracy of the Dexcom G7 Continuous Glucose Monitoring System in the ICU
Main objective:
The goal is to to determine the accuracy of Dexcom G7 Continuous glucose monitor system in critically ill patients, undergoing major abdominal surgery and solid organ transplantation, in the intensive care unit.
On admission to the intensive care unit or at the end of surgery, two Dexcom G7 sensors are placed in the infraclavicular position.
Sensor number 1 will be blinded and will only be active when paired with the receiver, without the ability to monitor glucose levels.
Sensor number 2 is used for continuous glucose monitoring and can be used to adjust the insulin dose.
Patients will wear the continuous glucose monitoring sensor for a maximum of 10 days, including the time spent in the intensive care unit and the immediate care unit. The study will not interfere with any usual care clinical workflows.
Calibration is only performed on an unblinded sensor. The reference method for calibration is the glucose from the blood glucose meter.
Calibrate on the first day of monitoring: 4 times a day after approximately 6 hours, or if the blood glucose reading from the blood glucose meter is not within the estimated error range of the continuous glucose monitor (difference greater than 1,5mmol/L).
Calibration on days 2 and 3 of monitoring: once in the morning, or when the meter's glucose reading is not within the estimated error range of the continuous glucose monitoring (difference greater than 1,5mmol/L) On subsequent days when the blood glucose meter reading is not within the estimated error range of continuous glucose monitoring (difference greater than 1,5mmol/L).
Hypothesis:
* Ho: No difference in mean absolute relative difference (MARD) between calibrated and non-calibrated sensors. * Ha: Calibrated sensors have lower mean absolute relative difference (δ = 4%, SD = 5%).
Further objectives:
To evaluate further aspects regarding the Dexcom G7 continuous glucose monitor system's performance in the intensive care unit (ICU), particularly in terms of sensitivity and specificity to detect hypo- and hyperglycaemic events, data availability, device deficiencies and safety.
To identify predictive factors of the accuracy of the Dexcom G7 continuous glucose monitor system in critically ill patients in the ICU.
Inclusion: Age 18 years or over; Intensive care unit admission; Requiring blood glucose monitoring for insulin therapy.
Exclusion: Physical or mental health condition precluding continuous wear of the continuous glucose monitor, as judged by the physician; High-dose ascorbic acid or acetaminophen > 4g/day.